<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2281801-B1" country="EP" doc-number="2281801" kind="B1" date="20140108" family-id="41402340" file-reference-id="315037" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587945" ucid="EP-2281801-B1"><document-id><country>EP</country><doc-number>2281801</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-09382123-A" is-representative="YES"><document-id mxw-id="PAPP154850137" load-source="docdb" format="epo"><country>EP</country><doc-number>09382123</doc-number><kind>A</kind><date>20090727</date><lang>ES</lang></document-id><document-id mxw-id="PAPP198208075" load-source="docdb" format="original"><country>EP</country><doc-number>09382123.9</doc-number><date>20090727</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140553246" ucid="EP-09382123-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>09382123</doc-number><kind>A</kind><date>20090727</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130830</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324317" load-source="docdb">C07C 213/08        20060101ALI20130409BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324318" load-source="docdb">C07C 219/28        20060101ALI20130409BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324319" load-source="docdb">C07C 229/38        20060101AFI20130409BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989633938" load-source="docdb" scheme="CPC">C07C 213/08        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989636845" load-source="docdb" scheme="CPC">C07C 229/38        20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132368468" lang="DE" load-source="patent-office">Verfahren zur Herstellung von 3,3-Diphenylpropylaminen</invention-title><invention-title mxw-id="PT132368469" lang="EN" load-source="patent-office">Process for obtaining 3,3-diphenylpropylamines</invention-title><invention-title mxw-id="PT132368470" lang="FR" load-source="patent-office">Procédé pour la préparation de 3,3-diphénylpropylamines</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1115670570" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CRYSTAL PHARMA SAU</last-name><address><country>ES</country></address></addressbook></applicant><applicant mxw-id="PPAR919531880" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CRYSTAL PHARMA, S.A.U.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919520985" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LORENTE BONDE-LARSEN ANTONIO</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919535964" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LORENTE BONDE-LARSEN, ANTONIO</last-name></addressbook></inventor><inventor mxw-id="PPAR919020777" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>LORENTE BONDE-LARSEN, ANTONIO</last-name><address><street>Crystal Pharma, S.A.U. Parque Tecnológico de Boecillo, Parcela 105A</street><city>47151 Boecillo - Valladolid</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919545913" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MARTIN PASCUAL PABLO</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919545460" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MARTIN PASCUAL, PABLO</last-name></addressbook></inventor><inventor mxw-id="PPAR919020778" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MARTÍN PASCUAL, Pablo</last-name><address><street>Crystal Pharma, S.A.U. Parque Tecnológico de Boecillo, Parcela 105A</street><city>47151 Boecillo - Valladolid</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919523556" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>LADERAS MUNOZ MARIO</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919510249" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>LADERAS MUNOZ, MARIO</last-name></addressbook></inventor><inventor mxw-id="PPAR919020781" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Laderas Muñoz, Mario</last-name><address><street>Crystal Pharma, S.A.U. Parque Tecnológico de Boecillo, Parcela 105A</street><city>47151 Boecillo - Valladolid</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919520429" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>GUTIERREZ FUENTES LUIS GERARDO</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919521046" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>GUTIERREZ FUENTES, LUIS GERARDO</last-name></addressbook></inventor><inventor mxw-id="PPAR919020779" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>Gutiérrez Fuentes, Luis Gerardo</last-name><address><street>Crystal Pharma, S.A.U. Parque Tecnológico de Boecillo, Parcela 105A</street><city>47151 Boecillo - Valladolid</city><country>ES</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919020782" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Crystal Pharma, S.A.U.</last-name><iid>101289491</iid><address><street>Parque Tecnológico de Boecillo, parcela 105A</street><city>47151 Boecillo - Valladolid</city><country>ES</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919020780" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>ABG Patentes, S.L.</last-name><iid>100061541</iid><address><street>Avenida de Burgos, 16D Edificio Euromor</street><city>28036 Madrid</city><country>ES</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549921988" load-source="docdb">AT</country><country mxw-id="DS549886962" load-source="docdb">BE</country><country mxw-id="DS549867888" load-source="docdb">BG</country><country mxw-id="DS549865516" load-source="docdb">CH</country><country mxw-id="DS549863901" load-source="docdb">CY</country><country mxw-id="DS549921989" load-source="docdb">CZ</country><country mxw-id="DS549886963" load-source="docdb">DE</country><country mxw-id="DS549863914" load-source="docdb">DK</country><country mxw-id="DS549863915" load-source="docdb">EE</country><country mxw-id="DS549779704" load-source="docdb">ES</country><country mxw-id="DS549867889" load-source="docdb">FI</country><country mxw-id="DS549865517" load-source="docdb">FR</country><country mxw-id="DS549886964" load-source="docdb">GB</country><country mxw-id="DS549863916" load-source="docdb">GR</country><country mxw-id="DS549886965" load-source="docdb">HR</country><country mxw-id="DS549921990" load-source="docdb">HU</country><country mxw-id="DS549779709" load-source="docdb">IE</country><country mxw-id="DS549863917" load-source="docdb">IS</country><country mxw-id="DS549865522" load-source="docdb">IT</country><country mxw-id="DS549863922" load-source="docdb">LI</country><country mxw-id="DS549867894" load-source="docdb">LT</country><country mxw-id="DS549795795" load-source="docdb">LU</country><country mxw-id="DS549867895" load-source="docdb">LV</country><country mxw-id="DS549867896" load-source="docdb">MC</country><country mxw-id="DS549795796" load-source="docdb">MK</country><country mxw-id="DS549795813" load-source="docdb">MT</country><country mxw-id="DS549779710" load-source="docdb">NL</country><country mxw-id="DS549780466" load-source="docdb">NO</country><country mxw-id="DS549779711" load-source="docdb">PL</country><country mxw-id="DS549867897" load-source="docdb">PT</country><country mxw-id="DS549921991" load-source="docdb">RO</country><country mxw-id="DS549779712" load-source="docdb">SE</country><country mxw-id="DS549865523" load-source="docdb">SI</country><country mxw-id="DS549780467" load-source="docdb">SK</country><country mxw-id="DS549780468" load-source="docdb">SM</country><country mxw-id="DS549795814" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63960378" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><u>Field of the Invention</u></heading><p id="p0001" num="0001">The invention relates to a process for obtaining 3,3-diphenylpropylamines, particularly Fesoterodine, as well as their enantiomers, solvates and salts.</p><heading id="h0002"><u>Background of the Invention</u></heading><p id="p0002" num="0002">3,3-diphenylpropylamines which act as muscarinic receptor antagonists and are useful in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity are known. Said compounds include N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, the (R) enantiomer of which is known as Tolterodine.</p><p id="p0003" num="0003">Another compound with a similar structure is 5-hydroxymethyl tolterodine, which is the main metabolite of Tolterodine (<nplcit id="ncit0001" npl-type="s"><text>Nilvebrant et al. Pharmacol. Toxicol, 1997, 81(4), 169-172</text></nplcit>), a potent muscarinic receptor antagonist (<patcit id="pcit0001" dnum="WO9411337A"><text>WO 94/11337</text></patcit>).
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="91" he="35" img-content="chem" img-format="tif"/></chemistry></p><p id="p0004" num="0004"><patcit id="pcit0002" dnum="WO99058478A"><text>WO 99/058478</text></patcit> describes the therapeutic usefulness of phenolic esters of said main metabolite of Tolterodine, especially of isobutyric acid 2-((R)-3-N,N-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester, known as Fesoterodine. Said document also describes the formation of their salts, particularly, the formation of Fesoterodine fumarate.
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="52" he="40" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="2"> --></p><p id="p0005" num="0005">The synthetic processes described in document <patcit id="pcit0003" dnum="WO9411337A"><text>WO 94/11337</text></patcit> for the synthesis of Fesoterodine include the one depicted in Reaction Scheme 1. Said process comprises the formation of a dihydrocoumarin intermediate by coupling in acid medium, a transformation which takes place with a low yield; subsequently the introduction of the hydroxymethyl group takes place by means of reaction of a bromo-derivative with an organomagnesium compound, followed by reduction to hydroxyl:
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="145" he="101" img-content="chem" img-format="tif"/></chemistry></p><p id="p0006" num="0006">The previous process has a number of drawbacks, since it is a long and expensive synthesis, which furthermore uses reagents which are difficult to handle such as organomagnesium compounds and Ni-Raney.</p><p id="p0007" num="0007">An alternative process for obtaining Fesoterodine is described in patent application <patcit id="pcit0004" dnum="WO9958478A"><text>WO 99/58478</text></patcit>, as is shown in Reaction Schemes 2 and 3. Said process comprises the formation of a chiral amide, on which a phenylmagnesium compound is added to give rise, after the hydrolysis of the amide group, to a chiral derivative of diphenylpropanoic acid, which by means of the formation of a tertiary amide and subsequent reduction gives<!-- EPO <DP n="3"> --> rise to the 3,3-diphenylpropylamino derivative intermediate (Reaction Scheme 2).
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="145" he="82" img-content="chem" img-format="tif"/></chemistry></p><p id="p0008" num="0008">The conversion of the bromo-derivative into the hydroxymethyl group is performed through a process of metalation, carbonation and subsequent reduction of the carboxyl group obtained. Finally, the deprotection of the phenol by hydrogenation of the benzyl group and its subsequent esterification give rise to Fesoterodine (Reaction Scheme 3).
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="138" he="63" img-content="chem" img-format="tif"/></chemistry></p><p id="p0009" num="0009">This synthesis again uses a large number of synthetic steps and uses chiral reagents, which usually have high costs, such<!-- EPO <DP n="4"> --> that the industrial application of the process is difficult.</p><p id="p0010" num="0010">This same patent application <patcit id="pcit0005" dnum="WO9958478A"><text>WO 99/58478</text></patcit> also describes a synthesis which has fewer reaction steps to reach Fesoterodine. The process comprises a Heck reaction and the addition of phenyl-Li in a Michael type addition. However, the 2-bromoanisole derivative is a not very accessible raw material, the use of Pd reagents which make its industrialization difficult being furthermore necessary. Additionally, the global process has low or moderate yields (Reaction Scheme 4).
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="142" he="68" img-content="chem" img-format="tif"/></chemistry></p><p id="p0011" num="0011">A different approach is described in European patent <patcit id="pcit0006" dnum="EP1289929B1"><text>EP 1289929 B1</text></patcit>, by means of a synthetic route in which a coupling in acid medium is initially performed, forming a dihydrocoumarin as a racemic intermediate. Said intermediate is then subjected to a stereoselective resolution process to obtain the suitable enantiomer. The latter is subsequently reduced to a lactol derivative, in which a diisoalkylamine is introduced by means of a reductive amination. Although the process is shorter, many synthesis steps are still required. In addition, the use of the aluminum tert-butoxide as a reducing agent is a considerable problem of toxicity and added cost to the process (Reaction Scheme 5).<!-- EPO <DP n="5"> -->
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="131" he="97" img-content="chem" img-format="tif"/></chemistry></p><p id="p0012" num="0012"><patcit id="pcit0007" dnum="WO2007138440A"><text>WO 2007/138440</text></patcit> describes a route of synthesis through the formation of a dihydrocoumarin intermediate, by means of a reaction needing conditions of reflux in toluene and toluene/hydrochloric acid for long time periods and with a low yield (Reaction Scheme 6).
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="132" he="77" img-content="chem" img-format="tif"/></chemistry></p><p id="p0013" num="0013">It is therefore necessary to solve the problems associated<!-- EPO <DP n="6"> --> with the processes belonging to the state of the art and provide an alternative process for obtaining Fesoterodine and 3,3-diphenylpropylamine analogs which improves the synthesis of the process using more cost-effective reagents and starting materials, which furthermore allow reducing the number of steps of the synthetic route which leads to obtaining them. Advantageously, said process must be applicable at industrial scale and must provide the desired product with good yield and quality.</p><heading id="h0003"><u>Summary of the Invention</u></heading><p id="p0014" num="0014">The invention faces the problem of providing an alternative process for obtaining 3,3-diphenylpropylamines, and particularly Fesoterodine, which overcomes all or part of the problems existing in the different aforementioned syntheses of the state of the art.</p><p id="p0015" num="0015">The solution provided by the present invention is based on the fact that the inventors have observed that it is surprisingly possible to efficiently obtain 3,3-diphenylpropylamines of general formula (I) (defined below), their enantiomers, solvates or salts, by means of the chemoselective reduction of the acid group against the ester group in compounds of general formula (V) (defined below). Furthermore, said compounds of general formula (V) can be suitably obtained by means of an esterification reaction.</p><p id="p0016" num="0016">Likewise, the present invention also provides a process for obtaining 3,3-diphenylpropylamines of general formula (I) (defined below), their enantiomers, solvates or salts, from commercial or easily accessible products, comprising: in the first place, a Friedel-Crafts type electrophilic aromatic substitution reaction between a compound of general formula (II) (defined below) and a compound of general formula (III) (defined below), whereby a compound of general formula (IV) (defined below) is obtained; if necessary, hydrolyzing the compound of general formula (IV) to give the acid of general formula (IV') (defined below); then, subjecting the compound obtained in the previous step to an esterification reaction of the hydroxyl<!-- EPO <DP n="7"> --> group to give rise to the compound of general formula (V); and finally, subjecting the compound of general formula (V) to a chemoselective reduction to give the compound of general formula (I), among which Fesoterodine is included. The previously indicated transformations are shown in Reaction Scheme 7.
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="147" he="84" img-content="chem" img-format="tif"/></chemistry>
wherein
<ul><li>R<sub>1</sub> is C<sub>1</sub>-C<sub>8</sub> alkyl;</li><li>R<sub>2</sub> is selected from CN, COOR<sub>5</sub> and CONR<sub>6</sub>R<sub>7</sub>; wherein
<ul><li>R<sub>5</sub> is selected from H, Cl and C<sub>1</sub>-C<sub>8</sub> alkyl; and</li><li>R<sub>6</sub> and R<sub>7</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl;</li></ul></li><li>R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.</li></ul></p><p id="p0017" num="0017">As a whole, a process such as the one provided by the present invention has the advantage of considerably reducing the number of synthetic steps with respect to the processes of the state of the art, while at the same time high yields are achieved with very simple steps. Likewise, said process is not toxic and allows starting from inexpensive and non-hazardous reactants, providing 3,3-diphenylpropylamines, and, particularly, Fesoterodine, with a good yield and pharmaceutical<!-- EPO <DP n="8"> --> quality. All of this contributes to reducing the overall cost of the process, making it commercially interesting and allowing it to be put into practice on an industrial level.</p><p id="p0018" num="0018">Therefore, in one aspect, the invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), their enantiomers, solvates or salts, comprising subjecting a compound of general formula (V) to a chemoselective reduction of the acid group against the ester group. In a particular preferred embodiment, said process is aimed at obtaining Fesoterodine.</p><p id="p0019" num="0019">In another aspect, the invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I) (defined below), their enantiomers, solvates or salts, from said compounds of general formula (II) and (III) (defined below), as has been previously mentioned.</p><p id="p0020" num="0020">In another additional aspect, the invention relates to the compounds of general formula (V), their enantiomers, solvates or salts, useful in obtaining 3,3-diphenylpropylamines of general formula (I). In a preferred embodiment, the invention relates to the compounds of formula (Va) (defined below), their enantiomers, solvates or salts, particularly useful in obtaining Fesoterodine.</p><heading id="h0004"><u>Detailed Description of the Invention</u></heading><heading id="h0005"><u>Definitions</u></heading><p id="p0021" num="0021">As used herein, the term "C<sub>1</sub>-C<sub>8</sub> alkyl" relates to a radical derived from a linear or branched alkane of 1 to 8 carbon atoms, for example, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, etc.</p><p id="p0022" num="0022">The invention also provides "salts" of the compounds described in the present description. By way of illustration, said salts can be acid addition salts, base addition salts or metal salts, and can be synthesized from the parent compounds containing a basic or acid moiety by means of conventional chemical processes known by the persons skilled in the art. Such salts are generally prepared, for example, by reacting the free acid or base forms of said compounds with a stoichiometric<!-- EPO <DP n="9"> --> amount of the suitable base or acid in water or in an organic solvent or in a mixture of the two. Non-aqueous media such as ether, ethyl acetate, ethanol, acetone, isopropanol or acetonitrile are generally preferred. Illustrative examples of said acid addition salts include inorganic acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc., organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, <i>p</i>-toluenesulfonate, camphorsulfonate, etc. Illustrative examples of base addition salts include inorganic base salts such as, for example, ammonium salts and organic base salts such as, for example, ethylenediamine, ethanolamine, <i>N</i>,<i>N-</i>dialkylenethanolamine, triethanolamine, glutamine, amino acid basic salts, etc. Illustrative examples of metal salts include, for example, sodium, potassium, calcium, magnesium, aluminum and lithium salts.</p><p id="p0023" num="0023">The salts can be pharmaceutically acceptable or not. The salts which are not pharmaceutically acceptable can be used as means for obtaining pharmaceutically acceptable salts.</p><p id="p0024" num="0024">Likewise, the compounds described in the present description can be obtained in the form of free base or acid or, alternatively, in the form of salt. In both cases they can be obtained in crystalline form, both as free compounds or as solvates (e.g., hydrates, alcoholates, etc.), both forms being included within the scope of the present invention. The solvation methods are generally known in the state of the art.</p><p id="p0025" num="0025">Compounds are "stereoisomers" when they are formed by the same atoms bound by the same sequence of bonds, but with different three-dimensional structures which are not interchangeable, such as for example, enantiomers or diastereoisomers.</p><p id="p0026" num="0026">As can be seen in the previous scheme, the compounds of general formulas (IV), (IV'), (V), (Va) and (I) comprise at least one asymmetric center and can therefore give rise to enantiomers with the spatial configuration (R) or (S). All the<!-- EPO <DP n="10"> --> individual enantiomers of said compounds as well as their mixtures, e.g., their racemic mixtures, are included within the scope of the present invention. Said individual enantiomers can be separated by means of conventional techniques. Although the invention can take place using mixtures of enantiomers of said compounds of general formulas (IV), (IV'), (V), (Va) and (I), for example, their racemic mixtures, in practice it is preferred to obtain a single enantiomer of formula (I). Therefore, the process preferably comprises a separation of enantiomers from a mixture thereof; said separation can occur in any of the intermediates of the process (compounds of general formulas (IV), (IV'), (V) or (Va)) or on the end product (compounds of general formula (I)).</p><p id="p0027" num="0027">Likewise, depending on the substituents, the compounds of general formulas (IV), (IV'), (V), (Va) and (I) can have more than one asymmetric center and can therefore give rise to diastereoisomers. All the individual diastereoisomers of said compounds as well as their mixtures, e.g., their racemic mixtures, are included within the scope of the present invention. The individual diastereoisomers can be separated by means of conventional techniques.</p><p id="p0028" num="0028">The term "pharmaceutically acceptable" relates to molecular entities and compositions being physiologically tolerable and normally not causing an allergic reaction or similar adverse reaction, such as gastric discomfort, dizziness and the like, when they are administered to a human being. Preferably, as used in this description, the term "pharmaceutically acceptable" means approved by a governmental regulatory agency or listed in the US pharmacopoeia or another generally recognized pharmacopoeia for use in animals, and more particularly in humans. Pharmaceutically acceptable salts can be obtained from salts which are not pharmaceutically acceptable.</p><p id="p0029" num="0029">Unless otherwise indicated, the compounds of the invention also include compounds which differ in the presence of one or more isotopically enriched atoms. By way of illustration, compounds having the structures defined herein, with the<!-- EPO <DP n="11"> --> exception of the substitution of at least one hydrogen with a deuterium or with tritium, or the substitution of at least one carbon with a carbon enriched in <sup>13</sup>C or <sup>14</sup>C, or at least one nitrogen with a nitrogen enriched in <sup>15</sup>N, are within the scope of this invention.</p><heading id="h0006"><u>Obtaining a compound of general formula (IV)</u></heading><p id="p0030" num="0030">The compounds of general formula (II) can be easily obtained by following Example 1 of application <patcit id="pcit0008" dnum="WO2007017544A"><text>WO 2007/017544</text></patcit> or by methods described in the state of the art such as: <nplcit id="ncit0002" npl-type="s"><text>Chemistry Letters, 1995, 1121-2</text></nplcit>; <nplcit id="ncit0003" npl-type="s"><text>Organic Chemistry and Biochemistry, 1995, 40 (3), 190-5</text></nplcit> and <nplcit id="ncit0004" npl-type="s"><text>Tetrahedron, 2000, 56, 4893-4905</text></nplcit>.</p><p id="p0031" num="0031">The compounds of general formula (III) are known and are commercially available.</p><p id="p0032" num="0032">The reaction of the propylenephenylamine of general formula (II) with the disubstituted aromatic hydrocarbon of general formula (III) is a Friedel-Crafts type electrophilic substitution reaction of the ortho position of the aromatic ring present in the compound of formula (III), and is carried out in a reaction medium comprising an acid acting as a catalyst of said Friedel-Crafts type electrophilic aromatic substitution reaction. Virtually any type of acid can be used. This reaction generally takes place with a high yield, typically comprised between 70% and 90%, thus contributing to the high overall yield of the process for obtaining the compound of formula (I) provided by this invention when it is carried out from said compounds of general formulas (II) and (III).</p><p id="p0033" num="0033">In a particular embodiment, said acid is an inorganic acid. Illustrative non-limiting examples of inorganic acids which can be used include hydrobromic, perchloric, sulfuric, hydrochloric, phosphoric acids, etc., and mixtures thereof. Said inorganic acids can be used in the form of solutions or aqueous suspensions.</p><p id="p0034" num="0034">In another particular embodiment, said acid is an organic acid, advantageously, a strong organic acid. Illustrative non-limiting examples of organic acids which can be used include sulfonic acids, such as p-toluenesulfonic acid, methanesulfonic<!-- EPO <DP n="12"> --> acid, trifluoromethanesulfonic acid, trifluoroacetic acid, etc., and mixtures thereof.</p><p id="p0035" num="0035">In another particular embodiment, the reaction medium comprises one or more inorganic acids and one or more organic acids. In a more particular embodiment, the reaction medium comprises an inorganic acid selected from the group consisting of hydrobromic acid, perchloric acid, sulfuric acid, hydrochloric acid, phosphoric acid and mixtures thereof, and an organic acid, such as, for example, acetic acid, trifluoroacetic acid, methanesulfonic acid, etc., and mixtures thereof.</p><p id="p0036" num="0036">The reaction is carried out in a suitable reaction medium. In a particular embodiment, said reaction medium comprises, in addition to the acid acting as a catalyst, a solvent, for example, acetic acid or an alcohol, such as an alcohol of 1 to 5 carbon atoms.</p><p id="p0037" num="0037">In a particular embodiment, the reaction medium comprises acetic acid as a solvent and sulfuric acid as a catalyst. In another particular embodiment, the reaction medium comprises an alcohol as a solvent, e.g., ethanol or isopropanol, and sulfuric acid as a catalyst.</p><p id="p0038" num="0038">The electrophilic aromatic substitution reaction between the compound of general formula (II) and the compound of general formula (III) is carried out in different conditions.</p><p id="p0039" num="0039">Thus, in a particular embodiment, the electrophilic aromatic substitution reaction between the compounds of general formulas (II) and (III) is carried out using between 1 and 6 equivalents of the compound of general formula (III) per equivalent of compound of general formula (II), in a reaction medium comprising an inorganic acid, for example, perchloric acid, sulfuric acid, hydrochloric acid, phosphoric acid or mixtures thereof, preferably sulfuric acid, at a temperature comprised between 80°C and the reflux temperature, preferably at the reflux temperature, in the presence of a solvent, for example, an alcohol (e.g., ethanol or isopropanol), or preferably acetic acid.</p><p id="p0040" num="0040">In another particular embodiment, the electrophilic<!-- EPO <DP n="13"> --> aromatic substitution reaction between the compounds of general formulas (II) and (III) is carried out using between 1 and 6 equivalents of the compound of general formula (III) per equivalent of compound of general formula (II), and an organic acid, for example, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, etc., preferably trifluoromethanesulfonic acid, and a solvent, such as acetic acid, at a temperature comprised between 60°C and the reflux temperature, preferably between 60°C and 90°C.</p><p id="p0041" num="0041">The compound of general formula (IV) has a chiral carbon and can therefore exist either in the form of its isolated (R) or (S) enantiomers or in the form of mixtures of said enantiomers. As used in this description, the term "mixtures of enantiomers" or "enantiomeric mixtures" includes both the racemic mixtures and the mixtures enriched in any one of the enantiomers. The (<i>R</i>) and (<i>S</i>) enantiomers of the compound of general formula (IV) obtained can be separated, if desired, by conventional resolution methods for mixtures of enantiomers, for example, by means of fractional crystallization, conventional chromatographic methods, etc. In a particular embodiment, the compound of general formula (IV) obtained by means of the process provided by this invention can be obtained in the form of a mixture of enantiomers, for example, in the form of a racemic mixture. Therefore, if desired, the mixture of enantiomers obtained can be resolved into its corresponding enantiomers to obtain the desired enantiomer. In a particular embodiment, said enantiomer is the enantiomer 2-[(1<i>R</i>)-3-<i>N</i>,<i>N-</i>diisopropylamine-1-phenylpropyl]-4-carboxyphenol ((<i>R</i>)-IV'a):
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="40" he="42" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="14"> --></p><p id="p0042" num="0042">The resolution of the mixture of enantiomers can be performed preferably by means of the use of optically active acids, which are capable of forming a salt with the amino group present in the compounds of general formula (IV), since said formed salts are diastereomeric, they can have solubilities different from one another which allow their separation by crystallization and subsequent recovery of the desired enantiomer by filtering the precipitated diastereomeric salt and neutralization thereof in basic or acid medium, or by means of the recovery from the mother liquor (if the salt formed with the enantiomer of interest is the one remaining in solution) and subsequent neutralization.</p><p id="p0043" num="0043">In theory, any optically active acid capable of forming diastereomeric salts with the amine of general formula (IV) can be used. Illustrative non-limiting examples of said acids comprise the use of for example L-tartaric acid, D-10-camphorsulfonic acid, D-ditoluyltartaric acid, (R)-(-)-acetoxylphenylacetic acid, etc.</p><p id="p0044" num="0044">In certain conditions the reaction between the compounds of general formulas (II) and (III) takes place with the hydrolysis of the R<sub>2</sub> substituent. It is thus possible to start from a compound of formula (III) in which R<sub>2</sub> is COOR<sub>5</sub>, wherein R<sub>5</sub> is Cl or C<sub>1</sub>-C<sub>8</sub> alkyl, or R<sub>2</sub> is CONR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub>, independently of one another, can be H or C<sub>1</sub>-C<sub>8</sub> alkyl, to give rise to a compound of general formula (IV) in which R<sub>2</sub> is a carboxylic acid group (COOH). It is also possible to start from a compound of general formula (III) in which R<sub>2</sub> is CN, to give rise to a product of general formula (IV) in which R<sub>2</sub> is a carboxylic acid group or a primary amide, depending on the reaction conditions.</p><heading id="h0007"><u>Obtaining a compound of general formula (IV')</u></heading><p id="p0045" num="0045">The compounds of general formula (IV) in which R<sub>2</sub> is a CN or COOR<sub>5</sub> group, wherein R<sub>5</sub> is Cl or C<sub>1</sub>-C<sub>8</sub> alkyl, or in which R<sub>2</sub> is CONR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub>, independently of one another, can be H or C<sub>1</sub>-C<sub>8</sub> alkyl, need to be initially transformed into a compound in which R<sub>2</sub> is a COOH group as a step prior to the<!-- EPO <DP n="15"> --> aforementioned esterification. These compounds are susceptible of being transformed into the corresponding compounds of general formula (IV') (compounds of general formula (IV) wherein R<sub>2</sub> is COOH) in basic or acid hydrolysis conditions.</p><p id="p0046" num="0046">Basic hydrolysis conditions include, by way of a non-limiting illustration, the use of bases such as NaOH or KOH, in an aqueous medium or in a medium comprising a water/solvent mixture, wherein the solvent can be an alcohol, such as an alcohol, for example, an alcohol of 1 to 5 carbon atoms, e.g., methanol (MeOH), ethanol (EtOH), etc., a glycol (e.g., ethylene glycol, etc.), an ether, e.g., tetrahydrofuran (THF), etc., at a temperature comprised between room temperature (approximately 18-22°C) and the reflux temperature of the chosen solvent.</p><p id="p0047" num="0047">Acid hydrolysis conditions include, by way of a non-limiting illustration, the use of acids such as hydrochloric acid, sulfuric acid, etc., in an aqueous medium or in a medium comprising a water/solvent mixture, wherein the solvent can be an alcohol, such as an alcohol, for example, an alcohol of 1 to 5 carbon atoms, e.g., methanol (MeOH), ethanol (EtOH), etc., an ether, e.g., tetrahydrofuran (THF), etc., and generally any solvent which is completely or miscible with water and which does not have groups susceptible of being hydrolyzed, at a temperature comprised between room temperature and the reflux temperature of the chosen solvent.</p><heading id="h0008"><u>Obtaining a compound of general formula (V)</u></heading><p id="p0048" num="0048">The compounds of general formula (IV) in which R<sub>2</sub> is COOH, i.e., the compounds of general formula (IV') can be subjected to an esterification reaction to give the compounds of general formula (V). The esterification can be performed either in acid medium or in basic medium by conventional methods known by the persons skilled in the art.</p><p id="p0049" num="0049">Said esterification reaction can be performed using carboxylic acids, esters, acid chlorides, acid anhydrides or other activated acid derivatives which react with the phenol group to give an ester. Reagents useful for the esterification reaction include, by way of a non-limiting illustration, those<!-- EPO <DP n="16"> --> depicted below:
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="48" he="16" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="53" he="15" img-content="chem" img-format="tif"/></chemistry>
wherein
<ul><li>R<sub>1</sub> and R', independently of one another, are C<sub>1</sub>-C<sub>8</sub> alkyl; and</li><li>X is a leaving group such as Cl, Br, imidazo, thioderivative, etc.</li></ul></p><p id="p0050" num="0050">The esterification in acid medium comprises, for example, the use of a carboxylic acid, a catalyst such as p-toluenesulfonic acid, and a solvent which allows removing the water formed during the reaction by means of distillation, or a solvent and a dehydrating agent such as sodium sulfate, molecular sieves, etc. Said reactions generally take place at reflux temperatures of the solvent.</p><p id="p0051" num="0051">The esterification is preferably performed in basic medium, using organic bases as triethylamine, diisopropylethylamine, pyridine, etc., in the presence of an activated acid such as an acid chloride, an anhydride, etc., in an organic non-protic solvent such as a halogenated hydrocarbon (e.g., dichloromethane (DCM), etc.), an ether (e.g., THF, etc.), an aromatic hydrocarbon (e.g., toluene, etc.), etc.</p><p id="p0052" num="0052">In a preferred embodiment, the esterification reaction is performed with triethylamine and an acid chloride, in DCM at room temperature, wherein between 1 and 3 equivalents of acid chloride are used.</p><p id="p0053" num="0053">Another preferred form of esterification comprises the use of inorganic bases, such as NaOH, KOH, sodium carbonate, potassium carbonate, etc., in a non-protic polar solvent such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), THF, etc., and an acid chloride, also at room temperature.</p><p id="p0054" num="0054">During the reaction, both the ester of general formula (V)<!-- EPO <DP n="17"> --> sought and another derivative which is the result of the formation of the ester with the hydroxyl group and the formation of the anhydride with the carboxyl group can be detected. This latter ester-anhydride type intermediate in aqueous conditions integrally evolves to the ester of general formula (V).</p><p id="p0055" num="0055">The compound of general formula (V) has a chiral carbon and can therefore exist in the form of its isolated (R) or (S) enantiomers or in the form of mixtures of said enantiomers. The obtained (R) and (S) enantiomers of the compound of formula (V) can be separated, if desired, by conventional resolution methods for mixtures of enantiomers, for example, by means of fractional crystallization, conventional chromatographic methods, etc. In a particular embodiment, the compound of general formula (V) obtained by means of the process provided by this invention can be obtained in the form of a mixture of enantiomers, for example, in the form of a racemic mixture or, alternatively, in the form of a mixture enriched in one of said enantiomers. Therefore, if desired, the mixture of enantiomers obtained can be resolved into its corresponding enantiomers to obtain the desired enantiomer. In a particular embodiment, said enantiomer is the enantiomer 2-[(1R)-3-<i>N</i>,<i>N</i>-diisopropylamine-1-phenylpropyl]-4-carboxyphenol isobutyrate ((<i>R</i>)-Va):
<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="48" he="42" img-content="chem" img-format="tif"/></chemistry></p><p id="p0056" num="0056">The resolution of the mixture of enantiomers can be performed by conventional methods known by the persons skilled in the art, preferably by means of the use of optically active acids which are capable of forming a salt with the amino group present in the compounds of general formula (V); since the salts thus formed are diastereomeric, they can have solubilities different from one other which allow their separation by<!-- EPO <DP n="18"> --> crystallization and subsequent recovery of the desired enantiomer by filtering the precipitated diastereomeric salt and neutralization thereof in basic or acid medium, or by means of the recovery from the mother liquor (if the salt formed with the enantiomer of interest is the one remaining in solution) and subsequent neutralization.</p><p id="p0057" num="0057">In theory, any optically active acid capable of forming diastereomeric salts with the amine of general formula (V) can be used. Illustrative non-limiting examples of said acids comprise the use of for example L-tartaric acid, D-10-camphorsulfonic acid, D-ditoluyltartaric acid, (<i>R</i>)-(-)-acetoxylphenylacetic acid, etc.</p><heading id="h0009"><u>Obtaining a compound of general formula (I)</u></heading><p id="p0058" num="0058">The compound of general formula (V) can be subjected to a chemoselective reduction to give rise to the compound of general formula (I) by means of the use of a reducing agent capable of (i.e., effective for) selectively reducing the carboxyl (-COOH) group present in the compound of general formula (V).</p><p id="p0059" num="0059">The compound of general formula (V) contains a carboxyl (-COOH) group and an ester (R<sub>1</sub>-C(O)O-) group susceptible of being reduced by means of a reducing agent. The reduction reaction on the compound of general formula (V) to give rise to the compound of general formula (I) must be chemoselective, such that the carboxyl group is preferably reduced without substantially affecting the ester group. Thus, a process for obtaining 3,3 diphenylpropylamines of general formula (I) is achieved with a smaller number of synthesis steps than those described in the state of the art.</p><p id="p0060" num="0060">Therefore, in the meaning used in this description, a reduction is chemoselective when the reducing agent preferably reduces the carboxyl group against the ester group; by way of illustration, the selectivity of the reducing agent towards the carboxyl group is equal to or greater than 80%, advantageously, equal to or greater than 85%, preferably, equal to or greater than 90%, more preferably, equal to or greater than 95%, even more preferably, equal to or greater than 96%, 97%, 98% or 99%.<!-- EPO <DP n="19"> --></p><p id="p0061" num="0061">This chemoselective reduction reaction can be carried out with different reducers, including hydrides, such as aluminum hydride (AlH<sub>3</sub>), etc., or, preferably, borane (compound of boron and hydrogen), their derivatives or precursors; illustrative non-limiting examples of said borane derivatives include diborane (B<sub>2</sub>H<sub>6</sub>), borane-tetrahydrofuran (BH<sub>3</sub>·THF) complexes [<nplcit id="ncit0005" npl-type="s"><text>N. M. Yoon, C. S. Pak, H. C. Brown, S. Krishnamurthy, and T. P. Stocky, J. Org. Chem., 38, 2786 (1973</text></nplcit>)], borane-dimethyl sulfide (BH<sub>3</sub>·Me<sub>2</sub>S) complexes [<nplcit id="ncit0006" npl-type="s"><text>L. M. Braun, R. A. Braun, H. R. Crissman, M. Opperman, and R. M. Adams, J. Org. Chem., 36, 2388 (1971</text></nplcit>)], etc. Likewise, illustrative non-limiting examples of borane precursors include compounds which generate borane or diborane in the reaction medium, such as, for example, NaBH<sub>4</sub>/I<sub>2</sub>, NaBH<sub>4</sub>/BF<sub>3</sub>(OEt)<sub>2</sub>, NaBH<sub>4</sub>/HCl, etc., and, in short, any reducer which generates borane or diborane in the reaction medium.</p><p id="p0062" num="0062">The chemoselective reduction reaction is suitably carried out in a suitable solvent, such as an ether, for example, an aliphatic ether (e.g., dimethoxyethane (DME), etc.), a cyclic ether (e.g., tetrahydrofuran (THF), methyl-THF, dioxane, etc.), an aromatic solvent (e.g., toluene, etc.), or mixtures of such solvents, for example, mixtures of ethers with aromatic solvents (e.g., THF/toluene, etc.).</p><p id="p0063" num="0063">Said chemoselective reduction reaction can be carried out at a temperature comprised between -75°C and 66°C, for a time period equal to or greater than 15 minutes, typically comprised between 30 minutes and 12 hours. These conditions collaborate in the reduction of the carboxyl group being selectively carried out without substantially affecting the ester group present in the compound of general formula (V).</p><p id="p0064" num="0064">In a preferred embodiment the chemoselective reduction reaction is performed using NaBH<sub>4</sub>/I<sub>2</sub> in THF as a solvent, at an initial temperature of 0°C and subsequently heating the reaction mixture to room or reflux temperature.</p><p id="p0065" num="0065">The compound of general formula (I) has a chiral carbon, and can therefore exist in the form of its isolated (R) or (S) enantiomers or in the form of mixtures of said enantiomers. The<!-- EPO <DP n="20"> --> obtained (R) and (S) enantiomers of the compound of formula (I) can be separated, if desired, by conventional resolution methods for mixtures of enantiomers, for example, by means of fractional crystallization, conventional chromatographic methods, etc. In a particular embodiment, the compound of general formula (I) obtained by means of the process provided by this invention can be obtained in the form of a mixture of enantiomers, for example, in the form of a racemic mixture or of a mixture enriched in one of the enantiomers. Therefore, if desired, the mixture of enantiomers obtained can be resolved into its corresponding enantiomers to obtain the desired enantiomer. In a particular embodiment, said enantiomer is the enantiomer R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl isobutyrate, known as Fesoterodine.</p><p id="p0066" num="0066">The resolution of the mixture of enantiomers can be performed by conventional methods, preferably by means of the use of optically active acids which are capable of forming a salt with the amino group present in the compounds of general formula (I); since the formed salts are diastereomeric, they can have solubilities different from one another which enable their separation by crystallization and subsequent recovery of the desired enantiomer by filtering the precipitated diastereomeric salt and neutralization thereof in basic or acid medium, or by means of the recovery from the mother liquor (if the salt formed with the enantiomer of interest is the one remaining in solution) and subsequent neutralization.</p><p id="p0067" num="0067">In theory, any optically active acid capable of forming diastereomeric salts with the amine of general formula (I) can be used; illustrative non-limiting examples of said acids comprise the use of for example L-tartaric acid, D-10-camphorsulfonic acid, D-ditoluyltartaric acid, (R)-(-)-acetoxylphenylacetic acid, etc.</p><p id="p0068" num="0068">Fesoterodine fumarate is a preferred compound of formula (I) according to the process of the present invention.</p><p id="p0069" num="0069">According to a particular embodiment of the process of the present invention, R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, i.e., methyl, ethyl,<!-- EPO <DP n="21"> --> propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; R<sub>1</sub> is preferably isopropyl.</p><p id="p0070" num="0070">According to another particular embodiment of the process of the present invention, R<sub>2</sub> is -COOR<sub>5</sub>, wherein R<sub>5</sub> is selected from H, Cl and C<sub>1</sub>-C<sub>8</sub> alkyl; R<sub>5</sub> is preferably H.</p><p id="p0071" num="0071">According to another particular embodiment of the process of the present invention, R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl, i.e., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; R<sub>2</sub> and R<sub>4</sub> are preferably isopropyl.</p><p id="p0072" num="0072">According to a preferred embodiment, the invention relates to a process for obtaining Fesoterodine:
<chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="48" he="35" img-content="chem" img-format="tif"/></chemistry>
its solvates or salts, comprising:
<ul><li>a) reacting a compound of formula (IIa)
<chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="42" he="24" img-content="chem" img-format="tif"/></chemistry>
with a compound of general formula (III)
<chemistry id="chem0016" num="0016"><img id="ib0016" file="imgb0016.tif" wi="12" he="34" img-content="chem" img-format="tif"/></chemistry>
wherein
<ul><li>R<sub>2</sub> is selected from CN, COOR<sub>5</sub> and CONR<sub>6</sub>R<sub>7</sub>; wherein
<ul><li>R<sub>5</sub> is selected from H, Cl and C<sub>1</sub>-C<sub>8</sub> alkyl; and</li><li>R<sub>6</sub> and R<sub>7</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl;<br/>
<!-- EPO <DP n="22"> -->to give a compound of general formula (IVa)
<chemistry id="chem0017" num="0017"><img id="ib0017" file="imgb0017.tif" wi="39" he="41" img-content="chem" img-format="tif"/></chemistry>
wherein R<sub>2</sub> has the previously indicated meaning;</li></ul></li></ul></li><li>b) if desired, separating the (R) enantiomer from the mixture of enantiomers of the compound of general formula (IVa);</li><li>c) if R<sub>2</sub> is different from COOH in the compound of general formula (IVa), subjecting said compound of general formula (IVa) to a hydrolysis to give rise to the compound of formula (IV'a)
<chemistry id="chem0018" num="0018"><img id="ib0018" file="imgb0018.tif" wi="40" he="42" img-content="chem" img-format="tif"/></chemistry></li><li>d) if desired, separating the (R) enantiomer from the mixture of enantiomers of the compound of formula (IV'a);</li><li>e) subjecting the compound obtained in the previous step to an esterification reaction of the hydroxyl group to give rise to the compound of formula (Va)
<chemistry id="chem0019" num="0019"><img id="ib0019" file="imgb0019.tif" wi="48" he="42" img-content="chem" img-format="tif"/></chemistry></li><li>f) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of the compound of general formula (Va);</li><li>g) subjecting said compound of formula (Va) to a<!-- EPO <DP n="23"> --> chemoselective reduction to give Fesoterodine; and</li><li>h) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of Fesoterodine and converting Fesoterodine into a salt or solvate thereof.</li></ul></p><p id="p0073" num="0073">In another aspect, the invention relates to a compound of general formula (V)
<chemistry id="chem0020" num="0020"><img id="ib0020" file="imgb0020.tif" wi="52" he="39" img-content="chem" img-format="tif"/></chemistry>
wherein
<ul><li>R<sub>1</sub> is C<sub>1</sub>-C<sub>8</sub> alkyl;</li><li>R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound;</li></ul>
its enantiomers, solvates or salts.</p><p id="p0074" num="0074">The compounds of general formula (V) are useful for obtaining the compounds of general formula (I).</p><p id="p0075" num="0075">In a particular embodiment of the compounds of general formula (V), R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, i.e., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; R<sub>1</sub> is preferably isopropyl.</p><p id="p0076" num="0076">In another particular embodiment of the compounds of general formula (V), R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl, i.e., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; R<sub>3</sub> and R<sub>4</sub> are preferably isopropyl.</p><p id="p0077" num="0077">The compound of formula (Va) [2-(3-<i>N</i>,<i>N</i>-diisopropylamine-1-phenylpropyl)-4-carboxyphenol isobutyrate]<!-- EPO <DP n="24"> -->
<chemistry id="chem0021" num="0021"><img id="ib0021" file="imgb0021.tif" wi="48" he="42" img-content="chem" img-format="tif"/></chemistry>
can be used in the preparation of Fesoterodine and is an additional aspect of this invention</p><p id="p0078" num="0078">In a particular embodiment, the compound of formula (Va) has the spatial configuration (<i>R</i>) [i.e., it is the enantiomer <i>R-</i>(+)-2-(3-<i>N</i>,<i>N</i>-diisopropylamino-1-phenylpropyl)-4-carboxyphenol isobutyrate].</p><p id="p0079" num="0079">The following examples illustrate the invention and must not be considered in a limiting sense thereof.</p><heading id="h0010"><u>EXAMPLE 1</u></heading><heading id="h0011"><u>Obtaining 2-(3-<i>N</i>,<i>N</i>-diisopropylamine-1-phenylpropyl)-4-carboxyphenol (IV'a)</u></heading><p id="p0080" num="0080"><chemistry id="chem0022" num="0022"><img id="ib0022" file="imgb0022.tif" wi="151" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0081" num="0081">Diisopropylamine (2.77 l, 19.65 mol) and sodium iodide (16.95 g, 0.13 mol) were loaded onto a solution of cinnamyl chloride (1 kg, 6.55 mol) in ethanol (3 l/kg) at 20/25°C. The mixture was heated at internal 80-85°C, the reaction conditions being maintained for 3-4 hours until the end of such reaction.</p><p id="p0082" num="0082">The mixture was cooled at 40-45°C and distilled to an internal volume of 1.3 l. The mixture was then cooled at 20-25°C, water (4 l) and toluene (3 l) was added and the pH was adjusted to 1.0-1.5. The phases were decanted and dichloromethane (4 l) was loaded onto the aqueous phase, adjusting the pH again to 11.5-12.0. The phases were decanted<!-- EPO <DP n="25"> --> and the organic phase was washed with water (4 l). Once the phases were decanted, the organic phase was distilled at atmospheric pressure to an internal volume of 1.3 l in order to then load heptane (0.5 l). Again, it was distilled to 1.3 l and heptane (2 l) was loaded.</p><p id="p0083" num="0083">The suspension which was obtained was filtered by a prelayer, which was washed with heptane (0.5 l). The filtered organic phase was distilled at atmospheric pressure to an internal volume of 1.3 l.</p><p id="p0084" num="0084">The amine content of the reaction mixture was determined by the potentiometric titration thereof.</p><p id="p0085" num="0085">Acetic acid (1.2 l/kg of amine), 4-hydroxybenzoic acid (0.63 kg/kg of amine, 1 equivalent), and, then, sulfuric acid (1.1 l/kg of amine, 4.5 equivalents) were loaded onto the mixture. It was heated at internal 80-85°C, the reaction conditions being maintained for 5-6 hours until the end of the reaction.</p><p id="p0086" num="0086">The reaction mixture was cooled to 35-40°C and water (10 l/kg of amine) and ethyl acetate (10 l/kg of amine) were loaded. The phases were decanted and the organic phase was washed out with water (5 l/kg). The aqueous phases were pooled; toluene (5 l/kg of amine) was loaded, the phases were decanted and n-butanol (10 l/kg of amine) was loaded onto the aqueous phase, the pH was adjusted to 7 and it was decanted.</p><p id="p0087" num="0087">The organic phase was distilled to an internal amine volume of 1.5-2.0 l/kg and then heptane (8 l/kg of amine) was loaded. The product which crystallized was cooled at 5-10°C, filtered and washed with heptane (5 l/kg of amine). The product was then dried in an oven with air circulation for 10-12 hours, obtaining a product with an overall molar yield of 40% and with a purity greater than 90%.<!-- EPO <DP n="26"> -->
<chemistry id="chem0023" num="0023"><img id="ib0023" file="imgb0023.tif" wi="58" he="45" img-content="chem" img-format="tif"/></chemistry>
NMR (<sup>1</sup>H) DMSO: H<sub>8</sub>: doublet 0.8-0.9 ppm 12H, H<sub>5</sub>: multiplet 2.0-2.1 ppm 2H, H<sub>6</sub>: multiplet 2.3 ppm 2H, H<sub>7</sub>: multiplet 2.8-3.0 ppm 2H, H<sub>4</sub>: triplet 4.3 ppm 1H, H<sub>1</sub>: doublet 6.8 ppm 1H, H<sub>11</sub>: multiplet 7.1 ppm 1H, H<sub>10-9</sub>: multiplet 7.1-7.3 ppm 4H, H<sub>2</sub>: doublet 7.5 ppm 1H, H<sub>3</sub>: singlet 7.8 ppm 1H.<br/>
NMR(<sup>13</sup>C) DMSO: 20.52; 20.57; 30.74; 36.11; 39.72; 48.04; 114.35; 125.56; 126.43; 128.59; 128.68; 129.02; 129.47; 129.77, 145.34; 157.76; 169.90.</p><heading id="h0012"><u>EXAMPLE 2</u></heading><heading id="h0013"><u>Obtaining 2-(3-<i>N</i>,<i>N</i>-diisopropylamine-1-phenylpropyl)-4-carboxyphenol isobutyrate (Va)</u></heading><p id="p0088" num="0088"><chemistry id="chem0024" num="0024"><img id="ib0024" file="imgb0024.tif" wi="124" he="38" img-content="chem" img-format="tif"/></chemistry></p><p id="p0089" num="0089">Triethylamine (0.80 1, 2.05 equivalents) was loaded onto a suspension of the amino acid obtained in Example 1 (IV'a) (1 kg) in dichloromethane (5 1). Then, without the reaction temperature exceeding 25-30°C, isobutyryl chloride (0.32 1, 1.1 equivalents) was loaded. The reaction conditions were maintained until the end of the reaction (1-2 hours). The reaction mixture was cooled and a NH<sub>4</sub>Cl solution (10%) (5 1) was loaded, the pH being adjusted to 7. The product was concentrated to dryness, obtaining a residue with a purity greater than 85% and a molar yield of 95-100%.<!-- EPO <DP n="27"> -->
<chemistry id="chem0025" num="0025"><img id="ib0025" file="imgb0025.tif" wi="69" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0090" num="0090">NMR (<sup>1</sup>H) DMSO: H<sub>10</sub>: doublet 0.9-1.1 ppm 12H, H<sub>1</sub>: dd 1.2-1.3 ppm 6H, H<sub>7</sub>: multiplet 2.2-2.4 ppm 2H, H<sub>8</sub>: multiplet 2.6 ppm 2H, H<sub>2</sub>: heptuplet 2.9 ppm 1H, H<sub>9</sub>: multiplet 3.2 ppm 2H, H<sub>6</sub>: triplet 4.2 ppm 1H, H<sub>3</sub>: doublet 7.1 ppm 1H, H<sub>13</sub>: multiplet 7.2 ppm 1H, H<sub>11</sub>-<sub>12</sub>: multiplet 7.2-7.3 ppm 4H, H<sub>4</sub>: doublet 7.8 ppm 1H, H<sub>5</sub>: singlet 8.1 ppm 1H.</p><p id="p0091" num="0091">NMR (<sup>13</sup>C) DMSO: 18.65; 18.79; 19.08; 19.25; 33.47; 34.22; 40.75; 43.54; 50.14; 122.50; 126.37; 127.71; 128.27, 128.47; 128.98; 132.55; 135.90; 143.19; 150.59; 167.80; 174.60.</p><heading id="h0014"><u>EXAMPLE 3</u></heading><heading id="h0015"><u>Obtaining isobutyric acid 2-(3-<i>N</i>,<i>N</i>-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester (Ia)</u></heading><p id="p0092" num="0092"><chemistry id="chem0026" num="0026"><img id="ib0026" file="imgb0026.tif" wi="111" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0093" num="0093">A 2 M solution of borane in THF (2.4 l, 2.0 equivalents) was slowly loaded onto a suspension at 20-25°C of the ester obtained in Example 2 (Va) (1 kg) in THF (5 1). Once the loading had ended, the reaction temperature was increased to 60-65°C, maintaining the conditions until the end of the reaction (3-5 h). The reaction mixture was cooled and a solution of NH<sub>4</sub>Cl (10%) (5 l) was loaded, the pH being adjusted to 7. Then, ethyl<!-- EPO <DP n="28"> --> acetate (5 1) was loaded and decanted. The organic phase was concentrated to dryness, obtaining a residue with a purity greater than 85% and a molar yield of 95-100%.</p></description><claims mxw-id="PCLM56983871" lang="DE" load-source="patent-office"><!-- EPO <DP n="35"> --><claim id="c-de-01-0001" num="0001"><claim-text>Ein Verfahren zur Herstellung einer Verbindung mit der allgemeinen Formel (I)
<chemistry id="chem0042" num="0042"><img id="ib0042" file="imgb0042.tif" wi="64" he="46" img-content="chem" img-format="tif"/></chemistry>
wobei
<claim-text>R<sub>1</sub> C<sub>1</sub>-C<sub>8</sub> Alkyl ist; und</claim-text>
<claim-text>R<sub>3</sub> und R<sub>4</sub>, unabhängig voneinander ausgewählt sind aus H und C<sub>1</sub>-C<sub>8</sub> Alkyl, oder zusammen einen 3- bis 7-gliedrigen Ring mit dem Stickstoffatom bilden, an das sie gebunden sind; seine Enantiomere, Solvate oder Salze, enthaltend das Unterwerfen einer Verbindung mit der allgemeinen Formel (V)
<chemistry id="chem0043" num="0043"><img id="ib0043" file="imgb0043.tif" wi="66" he="43" img-content="chem" img-format="tif"/></chemistry></claim-text>
wobei
<claim-text>R<sub>1</sub>, R<sub>3</sub> und R<sub>4</sub> die zuvor genannte Bedeutung besitzen,<br/>
einer chemoselektiven Reduktion.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Das Verfahren gemäß Anspruch 1, wobei die chemoselektive Reduktion mit einem Reduktionsmittel durchgeführt wird ausgewählt aus einem Hydrid, Boran, einem Boranderivat oder einer Boran-Vorstufe.<!-- EPO <DP n="36"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Das Verfahren gemäß Anspruch 2, wobei das Reduktionsmittel ausgewählt ist aus der Gruppe bestehend aus AlH<sub>3</sub>, BH<sub>3</sub>·THF, BH<sub>3</sub>·Me<sub>2</sub>S, NaBH<sub>4</sub>/I<sub>2</sub>, NaBH<sub>4</sub>/BF<sub>3</sub>(OEt)<sub>2</sub> und NaBH<sub>4</sub>/HCl.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Das Verfahren gemäß irgend einem der vorherigen Ansprüche 1 bis 3, zusätzlich enthaltend das Unterwerfen einer Verbindung mit der allgemeinen Formel (IV')
<chemistry id="chem0044" num="0044"><img id="ib0044" file="imgb0044.tif" wi="49" he="45" img-content="chem" img-format="tif"/></chemistry>
wobei
<claim-text>R<sub>3</sub> und R<sub>4</sub> die Bedeutung aufweisen wie in Anspruch 1 definiert;<br/>
einer Veresterung der Hydroxylgruppe mit einer Carbonsäure, einem Ester, einem Säurechlorid, einem Anhydrid oder irgend einem anderen geeigneten carboxylierten Derivat, um eine Verbindung mit der allgemeinen Formel (V) zu erhalten wie in Anspruch 1 definiert.</claim-text></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Das Verfahren gemäß Anspruch 4, wobei die Veresterung in einem Reaktionsmedium enthaltend ein basisches Medium durchgeführt wird.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Das Verfahren gemäß Anspruch 5, wobei das basische Medium Triethylamin, Diisopropylethylamin oder Pyridin enthält.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Das Verfahren gemäß Anspruch 6, wobei die Veresterung in einem Reaktionsmedium durchgeführt wird, enthaltend Triethylamin, ein Säurechlorid und Dichlormethan.<!-- EPO <DP n="37"> --></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Das Verfahren gemäß irgend einem der Ansprüche 1 bis 7, zusätzlich enthaltend die Unterwerfung einer Verbindung mit der allgemeinen Formel (IV)
<chemistry id="chem0045" num="0045"><img id="ib0045" file="imgb0045.tif" wi="59" he="43" img-content="chem" img-format="tif"/></chemistry>
wobei
<claim-text>R<sub>2</sub> ausgewählt ist aus CN, COOR<sub>5</sub> und CONR<sub>6</sub>R<sub>7</sub>; wobei
<claim-text>R<sub>5</sub> ausgewählt ist aus H, Cl und C<sub>1</sub>-C<sub>8</sub> Alkyl; und</claim-text>
<claim-text>R<sub>6</sub> und R<sub>7</sub>, unabhängig voneinander ausgewählt sind aus H und C<sub>1</sub>-C<sub>8</sub> Alkyl; und</claim-text></claim-text>
<claim-text>R<sub>3</sub> und R<sub>4</sub> die Bedeutung aufweisen wie in Anspruch 1 definiert;<br/>
einer Hydrolyse, um eine Verbindung mit der allgemeinen Formel (IV') zu erhalten wie in Anspruch 4 definiert.</claim-text></claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Das Verfahren gemäß irgend einem der Ansprüche 1 bis 8, zusätzlich enthaltend die Reaktion einer Verbindung mit der allgemeinen Formel (II)
<chemistry id="chem0046" num="0046"><img id="ib0046" file="imgb0046.tif" wi="62" he="23" img-content="chem" img-format="tif"/></chemistry>
wobei
<claim-text>R<sub>3</sub> und R<sub>4</sub> die Bedeutung aufweisen wie in Anspruch 1 definiert;<br/>
mit einer Verbindung mit der allgemeinen Formel (III)
<chemistry id="chem0047" num="0047"><img id="ib0047" file="imgb0047.tif" wi="29" he="37" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="38"> -->
wobei</claim-text>
<claim-text>R<sub>2</sub> die Bedeutung aufweist wie in Anspruch 8 definiert;</claim-text>
um eine Verbindung mit der allgemeinen Formel (IV) zu erhalten wie in Anspruch 8 definiert.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Das Verfahren gemäß irgend einem der vorherigen Ansprüche, zusätzlich enthaltend die Abtrennung eines Enantiomers der Verbindung mit der allgemeinen Formel (IV), (IV'), (V) oder (I), wie in den Ansprüchen 8, 4, und 1 entsprechend definiert.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Das Verfahren gemäß Anspruch 10, wobei das Enantiomer das (R) Enantiomer ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Ein Verfahren zur Herstellung von Fesoterodin
<chemistry id="chem0048" num="0048"><img id="ib0048" file="imgb0048.tif" wi="59" he="42" img-content="chem" img-format="tif"/></chemistry>
seiner Solvate, oder Salze, enthaltend:
<claim-text>a) Reagieren einer Verbindung mit der Formel (IIa)
<chemistry id="chem0049" num="0049"><img id="ib0049" file="imgb0049.tif" wi="56" he="28" img-content="chem" img-format="tif"/></chemistry>
mit einer Verbindung mit der allgemeinen Formel (III)
<chemistry id="chem0050" num="0050"><img id="ib0050" file="imgb0050.tif" wi="34" he="42" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="39"> -->
wobei
<claim-text>R<sub>2</sub> ausgewählt ist aus CN, COOR<sub>5</sub> und CONR<sub>6</sub>R<sub>7</sub>; wobei
<claim-text>R<sub>5</sub> ausgewählt ist aus H, Cl und C<sub>1</sub>-C<sub>8</sub> Alkyl; und</claim-text>
<claim-text>R<sub>6</sub> und R<sub>7</sub>, unabhängig voneinander ausgewählt sind aus H und C<sub>1</sub>-C<sub>8</sub> Alkyl;<br/>
um die Verbindung mit der Formel (IVa) zu erhalten
<chemistry id="chem0051" num="0051"><img id="ib0051" file="imgb0051.tif" wi="74" he="45" img-content="chem" img-format="tif"/></chemistry>
wobei R<sub>2</sub> die zuvor genannte Bedeutung aufweist;</claim-text></claim-text></claim-text>
<claim-text>b) falls gewünscht, Abtrennen des (R) Enantiomers von der Enantiomerenmischung der Verbindung mit der allgmeinen Formel (IVa) ;</claim-text>
<claim-text>c) wenn R<sub>2</sub> in der Verbindung mit der allgemeinen Formel (IVa) von COOH verschieden ist, Unterwerfen der Verbindung mit der Formel (IVa) einer Hydrolyse, um die Verbindung mit der Formel (IV'a) zu erhalten
<chemistry id="chem0052" num="0052"><img id="ib0052" file="imgb0052.tif" wi="52" he="46" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>d) falls gewünscht, Abtrennen des (R) Enantiomers von der Enantiomerenmischung der Verbindung mit der allgemeinen Formel (IV'a) ;</claim-text>
<claim-text>e) Unterwerfen der im vorherigen Schritt erhaltenen Verbindung einer Veresterung der Hydroxylgruppe, um die Verbindung (Va) zu erhalten<!-- EPO <DP n="40"> -->
<chemistry id="chem0053" num="0053"><img id="ib0053" file="imgb0053.tif" wi="60" he="55" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>f) falls gewünscht, Abtrennen des (R) Enantiomers von der Enantiomerenmischung der Verbindung mit der allgemeinen Formel (Va) ;</claim-text>
<claim-text>g) Unterwerfen der Verbindung mit der Formel (Va) einer chemoselektiven Reduktion, um die Verbindung mit der Formel (Ia) zu erhalten;
<chemistry id="chem0054" num="0054"><img id="ib0054" file="imgb0054.tif" wi="60" he="46" img-content="chem" img-format="tif"/></chemistry>
und</claim-text>
<claim-text>h) falls gewünscht, Abtrennen de (R) Enantiomers von der Enantiomerenmischung von Fesoterodin und Umwandlung von Fesoterodin in ein Salz oder Solvat davon.</claim-text></claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Eine Verbindung mit der allgemeinen Formel (V)
<chemistry id="chem0055" num="0055"><img id="ib0055" file="imgb0055.tif" wi="63" he="46" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="41"> -->
wobei
<claim-text>R<sub>1</sub> C<sub>1</sub>-C<sub>8</sub> Alkyl ist;</claim-text>
<claim-text>R<sub>3</sub> und R<sub>4</sub>, unabhängig voneinander ausgewählt sind aus H und C<sub>1</sub>-C<sub>8</sub> Alkyl, oder zusammen einen 3- bis 7-gliedrigen Ring mit dem Stickstoffatom bilden, an das sie gebunden sind;</claim-text>
seine Enantiomere, Solvate oder Salze.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Eine Verbindung gemäß Anspruch 13 mit der Formel (Va)
<chemistry id="chem0056" num="0056"><img id="ib0056" file="imgb0056.tif" wi="61" he="45" img-content="chem" img-format="tif"/></chemistry>
seine Enantiomere, Solvate oder Salze.</claim-text></claim></claims><claims mxw-id="PCLM56983872" lang="EN" load-source="patent-office"><!-- EPO <DP n="29"> --><claim id="c-en-01-0001" num="0001"><claim-text>A process for obtaining a compound of general formula (I)
<chemistry id="chem0027" num="0027"><img id="ib0027" file="imgb0027.tif" wi="61" he="50" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>1</sub> is C<sub>1</sub>-C<sub>8</sub> alkyl; and</claim-text>
<claim-text>R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound;<br/>
its enantiomers, solvates or salts, comprising subjecting a compound of general formula (V)
<chemistry id="chem0028" num="0028"><img id="ib0028" file="imgb0028.tif" wi="67" he="44" img-content="chem" img-format="tif"/></chemistry>
wherein</claim-text>
<claim-text>R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> have the previously indicated meaning, to a chemoselective reduction.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The process according to claim 1, wherein the chemoselective reduction is carried out with a reducing agent selected from a hydride, borane, a borane derivative or a borane precursor.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The process according to claim 2, wherein said reducing agent is selected from the group consisting of AlH<sub>3</sub>, BH<sub>3</sub>·THF, BH<sub>3</sub>·Me<sub>2</sub>S, NaBH<sub>4</sub>/I<sub>2</sub>, NaBH<sub>4</sub>/BF<sub>3</sub>(OEt)<sub>2</sub> and NaBH<sub>4</sub>/HCl.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The process according to any of the previous claims 1<!-- EPO <DP n="30"> --> to 3, additionally comprising subjecting a compound of general formula (IV')
<chemistry id="chem0029" num="0029"><img id="ib0029" file="imgb0029.tif" wi="59" he="43" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>3</sub> and R<sub>4</sub> have the meaning defined in claim 1; to an esterification reaction of the hydroxyl group with a carboxylic acid, an ester, an acid chloride, an anhydride or any other suitable carboxylated derivative, to obtain a compound of general formula (V) as defined in claim 1.</claim-text></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The process according to claim 4, wherein the esterification reaction is carried out in a reaction medium comprising a basic medium.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The process according to claim 5, wherein the basic medium comprises triethylamine, diisopropylethylamine or pyridine.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The process according to claim 6, wherein the esterification reaction is carried out in a reaction medium comprising triethylamine, an acid chloride and dichloromethane.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The process according to any of claims 1 to 7, additionally comprising subjecting a compound of general formula (IV)
<chemistry id="chem0030" num="0030"><img id="ib0030" file="imgb0030.tif" wi="54" he="47" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>2</sub> is selected from CN, COOR<sub>5</sub> and CONR<sub>6</sub>R<sub>7</sub>; wherein<!-- EPO <DP n="31"> -->
<claim-text>R<sub>5</sub> is selected from H, Cl and C<sub>1</sub>-C<sub>8</sub> alkyl; and</claim-text></claim-text>
<claim-text>R<sub>6</sub> and R<sub>7</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl; and<br/>
R<sub>3</sub> and R<sub>4</sub> have the meaning defined in claim 1;<br/>
to a hydrolysis reaction, to obtain a compound of general formula (IV') as defined in claim 4.</claim-text></claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The process according to any of claims 1 to 8, additionally comprising reacting a compound of general formula (II)
<chemistry id="chem0031" num="0031"><img id="ib0031" file="imgb0031.tif" wi="55" he="25" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>3</sub> and R<sub>4</sub> have the meaning defined in claim 1; with a compound of general formula (III)
<chemistry id="chem0032" num="0032"><img id="ib0032" file="imgb0032.tif" wi="32" he="35" img-content="chem" img-format="tif"/></chemistry>
wherein</claim-text>
<claim-text>R<sub>2</sub> has the meaning defined in claim 8;<br/>
to give a compound of general formula (IV) as defined in claim 8.</claim-text></claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The process according to any of the previous claims, additionally comprising the separation of an enantiomer of the compound of general formula (IV), (IV'), (V) or (I), as defined in claims 8, 4, and 1, respectively.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The process according to claim 10, wherein said enantiomer is the (R) enantiomer.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A process for obtaining Fesoterodine<!-- EPO <DP n="32"> -->
<chemistry id="chem0033" num="0033"><img id="ib0033" file="imgb0033.tif" wi="59" he="42" img-content="chem" img-format="tif"/></chemistry>
its solvates, or salts, comprising:
<claim-text>a) reacting a compound of formula (IIa)
<chemistry id="chem0034" num="0034"><img id="ib0034" file="imgb0034.tif" wi="53" he="29" img-content="chem" img-format="tif"/></chemistry>
with a compound of general formula (III)
<chemistry id="chem0035" num="0035"><img id="ib0035" file="imgb0035.tif" wi="30" he="37" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>2</sub> is selected from CN, COOR<sub>5</sub> and CONR<sub>6</sub>R<sub>7</sub>; wherein
<claim-text>R<sub>5</sub> is selected from H, Cl and C<sub>1</sub>-C<sub>8</sub> alkyl; and</claim-text>
<claim-text>R<sub>6</sub> and R<sub>7</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl;<br/>
to give the compound of formula (IVa)
<chemistry id="chem0036" num="0036"><img id="ib0036" file="imgb0036.tif" wi="60" he="43" img-content="chem" img-format="tif"/></chemistry>
wherein R<sub>2</sub> has the previously indicated meaning;</claim-text></claim-text></claim-text>
<claim-text>b) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of the compound of general formula (IVa);<!-- EPO <DP n="33"> --></claim-text>
<claim-text>c) if R<sub>2</sub> is different from COOH in the compound of general formula (IVa), subjecting said compound of formula (IVa) to a hydrolysis to give rise to the compound of formula (IV'a)
<chemistry id="chem0037" num="0037"><img id="ib0037" file="imgb0037.tif" wi="58" he="45" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>d) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of the compound of general formula (IV'a);</claim-text>
<claim-text>e) subjecting the compound obtained in the previous step to an esterification of the hydroxyl group to give rise to the compound (Va)
<chemistry id="chem0038" num="0038"><img id="ib0038" file="imgb0038.tif" wi="57" he="46" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>f) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of the compound of general formula (Va);</claim-text>
<claim-text>g) subjecting said compound of formula (Va) to a chemoselective reduction to give the compound of formula (Ia);
<chemistry id="chem0039" num="0039"><img id="ib0039" file="imgb0039.tif" wi="64" he="50" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="34"> -->
and</claim-text>
<claim-text>h) if desired, separating the (<i>R</i>) enantiomer from the mixture of enantiomers of Fesoterodine and converting Fesoterodine into a salt or solvate thereof.</claim-text></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A compound of general formula (V)
<chemistry id="chem0040" num="0040"><img id="ib0040" file="imgb0040.tif" wi="60" he="43" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>R<sub>1</sub> is C<sub>1</sub>-C<sub>8</sub> alkyl;</claim-text>
<claim-text>R<sub>3</sub> and R<sub>4</sub>, independently of one another, are selected from H and C<sub>1</sub>-C<sub>8</sub> alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound;</claim-text>
its enantiomers, solvates or salts.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A compound according to claim 13 of formula (Va)
<chemistry id="chem0041" num="0041"><img id="ib0041" file="imgb0041.tif" wi="60" he="45" img-content="chem" img-format="tif"/></chemistry>
its enantiomers, solvates or salts.</claim-text></claim></claims><claims mxw-id="PCLM56983873" lang="FR" load-source="patent-office"><!-- EPO <DP n="42"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Procédé pour obtenir un composé de formule générale (I)
<chemistry id="chem0057" num="0057"><img id="ib0057" file="imgb0057.tif" wi="63" he="47" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>R<sub>1</sub> est un alkyle en C<sub>1</sub> à C<sub>8</sub> ; et</claim-text>
<claim-text>R<sub>3</sub> et R<sub>4</sub>, indépendamment l'un de l'autre, sont choisi parmi H et un alkyle en C<sub>1</sub> à C<sub>8</sub>, ou ensemble forment un cycle de 3 à 7 chaînons avec l'azote auquel ils sont liés ;<br/>
ses énantiomères, solvatés ou sels, comprenant la soumission d'un composé de formule générale (V)
<chemistry id="chem0058" num="0058"><img id="ib0058" file="imgb0058.tif" wi="64" he="42" img-content="chem" img-format="tif"/></chemistry></claim-text>
dans laquelle
<claim-text>R<sub>1</sub>, R<sub>3</sub> et R<sub>4</sub> ont la signification indiquée précédemment, à une réduction chimiosélective.</claim-text><!-- EPO <DP n="43"> --></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Le procédé selon la revendication 1, dans lequel la réduction chimiosélective est réalisée avec un agent réducteur choisi parmi un hydrure, un borane, un dérivé du borane ou un précurseur de borane.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Le procédé selon la revendication 2, dans lequel ledit agent réducteur est choisi dans le groupe constitué par AlH<sub>3</sub>, BH<sub>3</sub>•THF, BH<sub>3</sub>•Me<sub>2</sub>S, NaBH<sub>4</sub>/I<sub>2</sub>, NaBH<sub>4</sub>/BF<sub>3</sub>(OEt)<sub>2</sub> et NaBH<sub>4</sub>/HCl.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Le procédé selon l'une quelconque des revendications précédentes 1 à 3, comprenant de plus la soumission d'un composé de formule générale (IV')
<chemistry id="chem0059" num="0059"><img id="ib0059" file="imgb0059.tif" wi="55" he="46" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>R<sub>3</sub> et R<sub>4</sub> ont la signification définie dans la revendication 1 ;</claim-text>
à une réaction d'estérification du groupe hydroxyle avec un acide carboxylique, un ester, un chlorure d'acide, un anhydride ou un quelconque dérivé carboxyle adapté, pour obtenir un dérivé de formule générale (V) tel que défini dans la revendication 1.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Le procédé selon la revendication 4, dans lequel la réaction d'estérification est réalisée dans un milieu réactionnel comprenant un milieu basique.<!-- EPO <DP n="44"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Le procédé selon la revendication 5, dans lequel le milieu basique comprend la triéthylamine, la diisopropyléthylamine ou la pyridine.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Le procédé selon la revendication 6, dans lequel la réaction d'estérification est réalisée dans un milieu réactionnel comprenant la triéthylamine, un chlorure d'acide et le dichlorométhane.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Le procédé selon l'une quelconque des revendications 1 à 7, comprenant de plus la soumission d'un composé de formule générale (IV)
<chemistry id="chem0060" num="0060"><img id="ib0060" file="imgb0060.tif" wi="54" he="44" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>R<sub>2</sub> est choisi parmi CN, COOR<sub>5</sub> et CONR<sub>6</sub>R<sub>7</sub> ; dans lesquels</claim-text>
<claim-text>R<sub>5</sub> est choisi parmi H, Cl et un alkyle en C<sub>1</sub> à C<sub>8</sub> ; et</claim-text>
<claim-text>R<sub>6</sub> et R<sub>7</sub>, indépendamment l'un de l'autre, sont choisis parmi H et un alkyle en C<sub>1</sub> à C<sub>8</sub> ; et</claim-text>
<claim-text>R<sub>3</sub> et R<sub>4</sub> ont la signification définie dans la revendication 1 ;</claim-text>
à une réaction d'hydrolyse, pour obtenir un composé de formule générale (IV') tel que défini dans la revendication 4.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Le procédé selon l'une quelconque des revendications 1 à 8, comprenant de<!-- EPO <DP n="45"> --> plus la réaction d'un composé de formule générale (II)
<chemistry id="chem0061" num="0061"><img id="ib0061" file="imgb0061.tif" wi="53" he="22" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>R<sub>3</sub> et R<sub>4</sub> ont la signification définie dans la revendication 1 ; avec un composé de formule générale (III)
<chemistry id="chem0062" num="0062"><img id="ib0062" file="imgb0062.tif" wi="31" he="38" img-content="chem" img-format="tif"/></chemistry></claim-text>
dans laquelle
<claim-text>R<sub>2</sub> a la signification définie dans la revendication 8 ;<br/>
pour donner un composé de formule générale (IV) tel que défini dans la revendication 8.</claim-text></claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Le procédé selon l'une quelconque des revendications précédentes, comprenant de plus la séparation d'un énantiomère d'un composé de formule générale (IV), (IV'), (V) ou (I), tel que défini dans le revendications 8, 4 et 1, respectivement.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Le procédé selon la revendication 10, dans lequel ledit énantiomère est<!-- EPO <DP n="46"> --> l'énantiomère (R).</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Un procédé pour obtenir la fésotérodine
<chemistry id="chem0063" num="0063"><img id="ib0063" file="imgb0063.tif" wi="55" he="44" img-content="chem" img-format="tif"/></chemistry>
ses solvates ou sels, comprenant :
<claim-text>a) la réaction d'un composé de formule (IIa)
<chemistry id="chem0064" num="0064"><img id="ib0064" file="imgb0064.tif" wi="50" he="36" img-content="chem" img-format="tif"/></chemistry>
avec un composé de formule générale (III)<br/>
dans laquelle
<chemistry id="chem0065" num="0065"><img id="ib0065" file="imgb0065.tif" wi="26" he="44" img-content="chem" img-format="tif"/></chemistry>
<claim-text>R<sub>2</sub> est choisi parmi CN, COOR<sub>5</sub> et CONR<sub>6</sub>R<sub>7</sub> ; dans lesquels</claim-text>
<claim-text>R<sub>5</sub> est choisi parmi H, Cl et un alkyle en C<sub>1</sub> à C<sub>8</sub> ;<!-- EPO <DP n="47"> --></claim-text>
<claim-text>R<sub>6</sub> et R<sub>7</sub>, indépendamment l'un de l'autre, sont choisis parmi H et un alkyle en C<sub>1</sub> à C<sub>8</sub> ;<br/>
pour donner le composé de formule (IVa)
<chemistry id="chem0066" num="0066"><img id="ib0066" file="imgb0066.tif" wi="52" he="46" img-content="chem" img-format="tif"/></chemistry>
dans laquelle R<sub>2</sub> a la signification indiquée précédemment ;</claim-text></claim-text>
<claim-text>b) si on le souhaite, la séparation de l'énantiomère (R) du mélange d'énantiomères du composé de formule générale (IVa) ;</claim-text>
<claim-text>c) si R<sub>2</sub> est différent de COOH dans le composé de formule générale (IVa), la soumission dudit composé de formule (IVa) à une hydrolyse pour donner naissance au composé de formule (IV'a)
<chemistry id="chem0067" num="0067"><img id="ib0067" file="imgb0067.tif" wi="55" he="47" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>d) si on le souhaite, la séparation de l'énantiomère (R) du mélange d'énantiomères du composé de formule générale (IV'a) ;</claim-text>
<claim-text>e) la soumission du composé obtenu dans l'étape précédente à une estérification du groupe hydroxyle pour donner naissance au composé (Va)<!-- EPO <DP n="48"> -->
<chemistry id="chem0068" num="0068"><img id="ib0068" file="imgb0068.tif" wi="59" he="49" img-content="chem" img-format="tif"/></chemistry></claim-text>
<claim-text>f) si on le souhaite, la séparation de l'énantiomère (R) du mélange d'énantiomères du composé de formule générale (Va) ;</claim-text>
<claim-text>g) la soumission dudit composé de formule (Va) à une réduction chimiosélective pour donner le composé de formule (Ia) ;
<chemistry id="chem0069" num="0069"><img id="ib0069" file="imgb0069.tif" wi="50" he="47" img-content="chem" img-format="tif"/></chemistry>
et</claim-text>
<claim-text>h) si on le souhaite, la séparation de l'énantiomère (R) du mélange d'énantiomères de fésotérodine et la conversion de la fésotérodine en un sel ou un solvate associé.</claim-text></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Un composé de formule générale (V)<!-- EPO <DP n="49"> -->
<chemistry id="chem0070" num="0070"><img id="ib0070" file="imgb0070.tif" wi="66" he="46" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>R<sub>1</sub> est un alkyle en C<sub>1</sub> à C<sub>8</sub> ;</claim-text>
<claim-text>R<sub>3</sub> et R<sub>4</sub>, indépendamment l'un de l'autre, sont choisis parmi H et un alkyle en C<sub>1</sub> à C<sub>8</sub>, ou ensemble forment un cycle de 3 à 7 chaînons avec l'azote auquel ils sont liés ;</claim-text>
ses énantiomères, solvates ou sels.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Un composé selon la revendication 13 de formule (Va)
<chemistry id="chem0071" num="0071"><img id="ib0071" file="imgb0071.tif" wi="63" he="44" img-content="chem" img-format="tif"/></chemistry>
ses énantiomères, solvates ou sels.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
